{"downloaded": true, "htmlmade": false, "full": {"id": "30477009", "source": "MED", "pmid": "30477009", "pmcid": "PMC6440717", "fullTextIdList": {"fullTextId": "PMC6440717"}, "doi": "10.1001/jamaoncol.2018.5457", "title": "Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.", "authorString": "Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O.", "authorList": {"author": [{"fullName": "Kazandjian D", "firstName": "Dickran", "lastName": "Kazandjian", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}}}, {"fullName": "Korde N", "firstName": "Neha", "lastName": "Korde", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City."}}}, {"fullName": "Mailankody S", "firstName": "Sham", "lastName": "Mailankody", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City."}}}, {"fullName": "Hill E", "firstName": "Elizabeth", "lastName": "Hill", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}}}, {"fullName": "Figg WD", "firstName": "William D", "lastName": "Figg", "initials": "WD", "authorId": {"@type": "ORCID", "#text": "0000-0003-2428-5613"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Pharmacokinetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}}}, {"fullName": "Roschewski M", "firstName": "Mark", "lastName": "Roschewski", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}}}, {"fullName": "Landgren O", "firstName": "Ola", "lastName": "Landgren", "initials": "O", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0003-2428-5613"}}, "dataLinksTagsList": {"dataLinkstag": ["altmetrics", "supporting_data"]}, "journalInfo": {"issue": "12", "volume": "4", "journalIssueId": "2760428", "dateOfPublication": "2018 Dec", "monthOfPublication": "12", "yearOfPublication": "2018", "printPublicationDate": "2018-12-01", "journal": {"title": "JAMA oncology", "ISOAbbreviation": "JAMA Oncol", "medlineAbbreviation": "JAMA Oncol", "NLMid": "101652861", "ISSN": "2374-2437", "ESSN": "2374-2445"}}, "pubYear": "2018", "pageInfo": "1781-1783", "affiliation": "Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Letter", "Clinical Trial, Phase II", "research-article"]}, "grantsList": {"grant": {"grantId": "P30 CA008748", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DI", "qualifierName": "diagnosis", "majorTopic_YN": "N"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm Recurrence, Local", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm, Residual"}, {"majorTopic_YN": "N", "descriptorName": "Dexamethasone", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Oligopeptides", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Neoadjuvant Therapy"}, {"majorTopic_YN": "N", "descriptorName": "Remission Induction"}, {"majorTopic_YN": "N", "descriptorName": "Follow-Up Studies"}, {"majorTopic_YN": "N", "descriptorName": "Drug Resistance, Neoplasm", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Lenalidomide", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Progression-Free Survival"}]}, "chemicalList": {"chemical": [{"name": "Oligopeptides", "registryNumber": "0"}, {"name": "Dexamethasone", "registryNumber": "7S5I7G3JQL"}, {"name": "lenalidomide", "registryNumber": "F0P408N6V4"}, {"name": "carfilzomib", "registryNumber": "72X6E3J5AR"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1001/jamaoncol.2018.5457"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6440717"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1001/jamaoncol.2018.5457"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "N", "hasBook": "N", "hasSuppl": "N", "citedByCount": "9", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-10-22", "dateOfCreation": "2018-11-27", "firstIndexDate": "2018-11-27", "fullTextReceivedDate": "2020-07-11", "dateOfRevision": "2020-03-09", "firstPublicationDate": "2018-12-01", "embargoDate": "2019-11-21"}, "journaltitle": "JAMA oncology", "authorinfo": ["Kazandjian D", "Korde N", "Mailankody S", "Hill E", "Figg WD", "Roschewski M", "Landgren O"], "title": "Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial."}